The 36-month beta value for ANAB is also noteworthy at -0.00. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for ANAB is 25.91M, and at present, short sellers hold a 28.28% of that float. The average trading volume of ANAB on January 23, 2025 was 674.43K shares.
ANAB) stock’s latest price update
AnaptysBio Inc (NASDAQ: ANAB)’s stock price has dropped by -4.15 in relation to previous closing price of 16.88. Nevertheless, the company has seen a gain of 8.52% in its stock price over the last five trading days. zacks.com reported 2025-01-13 that AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ANAB’s Market Performance
AnaptysBio Inc (ANAB) has seen a 8.52% rise in stock performance for the week, with a 5.48% gain in the past month and a -53.74% plunge in the past quarter. The volatility ratio for the week is 6.63%, and the volatility levels for the past 30 days are at 7.01% for ANAB. The simple moving average for the last 20 days is 11.11% for ANAB’s stock, with a simple moving average of -39.12% for the last 200 days.
Analysts’ Opinion of ANAB
Many brokerage firms have already submitted their reports for ANAB stocks, with H.C. Wainwright repeating the rating for ANAB by listing it as a “Neutral.” The predicted price for ANAB in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 11, 2024 of the previous year 2024.
H.C. Wainwright gave a rating of “Buy” to ANAB, setting the target price at $55 in the report published on July 22nd of the previous year.
ANAB Trading at -11.48% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.83% of loss for the given period.
Volatility was left at 7.01%, however, over the last 30 days, the volatility rate increased by 6.63%, as shares surge +7.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.15% lower at present.
During the last 5 trading sessions, ANAB rose by +8.52%, which changed the moving average for the period of 200-days by -24.04% in comparison to the 20-day moving average, which settled at $14.56. In addition, AnaptysBio Inc saw 22.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANAB starting from EcoR1 Capital, LLC, who purchase 65,184 shares at the price of $12.92 back on Dec 30 ’24. After this action, EcoR1 Capital, LLC now owns 7,860,180 shares of AnaptysBio Inc, valued at $842,060 using the latest closing price.
EcoR1 Capital, LLC, the Director of AnaptysBio Inc, purchase 13,268 shares at $12.93 during a trade that took place back on Dec 31 ’24, which means that EcoR1 Capital, LLC is holding 7,873,448 shares at $171,513 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -2.58 for the present operating margin
- 0.96 for the gross margin
The net margin for AnaptysBio Inc stands at -2.9. The total capital return value is set at -0.33. Equity return is now at value -161.81, with -33.78 for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -6.25. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -3.92.
Currently, EBITDA for the company is -143.16 million with net debt to EBITDA at 1.39. When we switch over and look at the enterprise to sales, we see a ratio of 5.55. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.23.
Conclusion
In summary, AnaptysBio Inc (ANAB) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
